Inside Life Sciences

Inside Life Sciences

Issue 3
3100Infliximab: battle of the biosimilars

Infliximab: battle of the biosimilars

On 23 May, the CMA issued a statement of objections, which is a provisional finding that Merck Sharp & Dohme Limited (MSD) has breached UK competition law by abusing its dominant position.

Read more
3102Using private prosecutions to tackle counterfeit drugs

Using private prosecutions to tackle counterfeit drugs

As rights holders, the protection of your brand and IP are of paramount importance.

Read more
3105SPC and patent research exemptions consultation: views sought from across industry

SPC and patent research exemptions consultation: views sought from across industry

A wide-ranging consultation on a 'recalibration' of the EU regime for supplementary protection certificates and patent research exemptions has been launched by the European Commission.

Read more
3108Future of the EMA and medicines regulation in the UK

Future of the EMA and medicines regulation in the UK

On 4 December 2017, we are holding a panel discussion at Mishcon de Reya on the future of medicines regulation in the UK post-Brexit.

Read more
3110Civil litigation: a proven tool for the agrochemicals industry

Civil litigation: a proven tool for the agrochemicals industry

Recent reports from Europol regarding the seizure of 122 tonnes of illegal pesticides in the EU highlight that the problem of illegal pesticides is substantial, with no signs of it abating.

Read more
3136Health apps: Patient empowerment, but at what cost?

Health apps: Patient empowerment, but at what cost?

With the NHS increasingly prescribing health apps that assist with the management of particular health conditions, and Health Secretary, Jeremy Hunt, revealing ambitious plans to provide patients with access to their medical records through apps by 2018

Read more
3138Restructuring doesn’t have to be a messy ordeal

Restructuring doesn’t have to be a messy ordeal

A company's decision to restructure can be prompted by a number of different things – it could be as a consequence of success, the result of disagreements, or simply because of commercial imperatives.

Read more
3141Patents Court considers new approach to scope of claims in validity context

Patents Court considers new approach to scope of claims in validity context

In August 2017, the Supreme Court issued its much-anticipated decision in Actavis v Lilly, substantially revising the approach to determining the scope of protection of patent claims in infringement cases, including the role to be played by the doctrine of equivalents.

Read more

Previous Issues

Prev
 
Next

Services

How can we help you?

How can we help you?

Subscribe: I'd like to keep in touch

If your enquiry is urgent please call +44 20 3321 7000

Crisis Hotline

Emergency number:

Tel: +44 80 0260 0546

I'm a client

Please enter your first name
Please enter your last name
Please enter your enquiry
Please enter a value

I'm looking for advice

Please enter your first name
Please enter your last name
Please enter your enquiry
Please select a department
Please select a contact method

Something else

Please enter your first name
Please enter your last name
Please enter your enquiry
Please select your contact method of choice